Page last updated: 2024-10-15

alamethicin

Description

Alamethicin: A cyclic nonadecapeptide antibiotic that can act as an ionophore and is produced by strains of Trichoderma viride. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16132042
CHEMBL ID438243
MeSH IDM0000618

Synonyms (20)

Synonym
f-50
brn 5213858
alamethicin (synthetic trichoderma viride)
u 22324
alamethicin f 30
alamethicin i
antibiotic u 22324
l-glutamamide, n-acetyl-2-methylalanyl-l-prolyl-2-methylalanyl-l-alanyl-2-methylalanyl-l-alanyl-l-glutaminyl-2-methylalanyl-l-valyl-2-methylalanylglycyl-l-leucyl-2-methylalanyl-l-prolyl-l-valyl-2-methylalanyl-2-methylalanyl-l-alpha-glutamyl-n1-(1-(hydroxy
alamethicin gamma
alamethicin
59588-86-2
CHEMBL438243
27061-78-5
antibiotic u-22324
alamethicin (u-22324)
HMS3402F22
AKOS030213155
mfcd00151517
J-016661
Q4705902

Research Excerpts

Overview

Alamethicin is a 19-amino-acid residue hydrophobic peptide of the peptaibol family that has been the object of numerous studies for its ability to produce voltage-dependent ion channels in membranes. It is believed to kill bacteria through pore formation in the inner membranes.

ExcerptReference
"Alamethicin is an antibiotic peptide comprising 20 amino acid residues and functions as an ion channel in biological membranes. "( NMR studies on the conformation, stability and dynamics of alamethicin in methanol.
Miura, Y, 2020
)
"Alamethicin is a 19-amino-acid residue hydrophobic peptide of the peptaibol family that has been the object of numerous studies for its ability to produce voltage-dependent ion channels in membranes. "( Alamethicin in bicelles: orientation, aggregation, and bilayer modification as a function of peptide concentration.
Bortolus, M; De Zotti, M; Formaggio, F; Maniero, AL, 2013
)
"Alamethicin is a 20-amino-acid, α-helical antimicrobial peptide that is believed to kill bacteria through pore formation in the inner membranes. "( Antimicrobial peptide alamethicin insertion into lipid bilayer: a QCM-D exploration.
Camesano, TA; Nagarajan, R; Wang, KF, 2014
)
"Alamethicin is a well-studied antimicrobial peptide (AMP) that kills Gram-positive bacteria. "( Single-cell, time-resolved study of the effects of the antimicrobial peptide alamethicin on Bacillus subtilis.
Barns, KJ; Weisshaar, JC, 2016
)
"Alamethicin (Alm) is a 19-mer antimicrobial peptide produced by fungus Trichoderma viride. "( Communication: Alamethicin can capture lipid-like molecules in the membrane.
Afanasyeva, EF; Dzuba, SA; Syryamina, VN, 2017
)
"Alamethicin (Alm) is a linear peptide antibiotic of great interest for its capability to form self-assembled ion channels in lipid membranes. "( PELDOR conformational analysis of bis-labeled alamethicin aggregated in phospholipid vesicles.
De Zotti, M; Milov, AD; Raap, J; Samoilova, RI; Toniolo, C; Tsvetkov, YD, 2008
)
"Alamethicin is a 20-residue peptaibiotic that induces voltage-dependent ion channels in lipid membranes. "( Orientation and peptide-lipid interactions of alamethicin incorporated in phospholipid membranes: polarized infrared and spin-label EPR spectroscopy.
Marsh, D, 2009
)
"Alamethicin is a 20-residue, hydrophobic, helical peptide, which forms voltage-sensitive ion channels in lipid membranes. "( Intramembrane water associated with TOAC spin-labeled alamethicin: electron spin-echo envelope modulation by D2O.
Bartucci, R; Guzzi, R; Marsh, D; Sportelli, L, 2009
)
"Alamethicin (ALA) is an ion channel-forming peptide mixture from the fungus Trichoderma viride that can induce volatile emission and increase endogenous levels of jasmonic acid (JA) and salicylic acid in plants."( Comparing induction at an early and late step in signal transduction mediating indirect defence in Brassica oleracea.
Bruinsma, M; Dicke, M; Mumm, R; Pang, B; van Loon, JJ, 2009
)
"Alamethicin is a membrane-active peptide isolated from the beneficial root-colonising fungus Trichoderma viride. "( Trichoderma viride cellulase induces resistance to the antibiotic pore-forming peptide alamethicin associated with changes in the plasma membrane lipid composition of tobacco BY-2 cells.
Aidemark, M; Andreasson, E; Rasmusson, AG; Sandelius, AS; Stålbrand, H; Tjellström, H; Widell, S, 2010
)
"Alamethicin is an antimicrobial peptide that forms stable channels with well-defined conductance levels. "( Analysis and evaluation of channel models: simulations of alamethicin.
Hess, B; Sansom, MS; Tieleman, DP, 2002
)
"Alamethicin K18 is a covalently linked alamethicin dimer in which the glutamine residue at position 18 in each helix has been replaced by a lysine residue. "( Understanding pH-dependent selectivity of alamethicin K18 channels by computer simulation.
Borisenko, V; Sansom, MS; Tieleman, DP; Woolley, GA, 2003
)
"Alamethicin is a hydrophobic helical peptide of 20 residues, which oligomerizes to form ion-conducting channels in membranes. "( Implicit solvent model estimates of the stability of model structures of the alamethicin channel.
Ben-Tal, N; Kessel, A; Tieleman, DP, 2004
)
"Alamethicin is a well-studied channel-forming peptide that has a prototypical amphipathic helix structure. "( Interactions of membrane-active peptides with thick, neutral, nonzwitterionic bilayers.
Discher, DE; Goulian, M; Janmey, P; Lal, J; Vijayan, K, 2005
)
"Alamethicin is a 19-amino-acid residue hydrophobic peptide that produces voltage-dependent ion channels in membranes. "( TOAC spin labels in the backbone of alamethicin: EPR studies in lipid membranes.
Jost, M; Marsh, D; Peggion, C; Toniolo, C, 2007
)
"Alamethicin is a 19-residue hydrophobic peptide, which is extended by a C-terminal phenylalaninol but lacks residues that might anchor the ends of the peptide at the lipid-water interface. "( Lipid chain-length dependence for incorporation of alamethicin in membranes: electron paramagnetic resonance studies on TOAC-spin labeled analogs.
Jost, M; Marsh, D; Peggion, C; Toniolo, C, 2007
)
"Alamethicin F50/5 is a hydrophobic peptide that is devoid of charged residues and that induces voltage-dependent ion channels in lipid membranes. "( Backbone dynamics of alamethicin bound to lipid membranes: spin-echo electron paramagnetic resonance of TOAC-spin labels.
Bartucci, R; De Zotti, M; Guzzi, R; Marsh, D; Sportelli, L; Toniolo, C, 2008
)
"Alamethicin is a 20 amino acid peptide that produces a voltage-dependent conductance in membranes. "( Structure of micelle-associated alamethicin from 1H NMR. Evidence for conformational heterogeneity in a voltage-gated peptide.
Cafiso, DS; Ellena, JF; Franklin, JC; Jayasinghe, S; Kelsh, LP, 1994
)
"Alamethicin is a 20-amino-acid peptide that produces a voltage-dependent conductance in membranes. "( Collisions between helical peptides in membranes monitored using electron paramagnetic resonance: evidence that alamethicin is monomeric in the absence of a membrane potential.
Barranger-Mathys, M; Cafiso, DS, 1994
)
"Alamethicin was shown to be a highly effective activator of glucuronidation activity; atRA and 5,6-epoxy-atRA glucuronidation rates were increased 2- and 3-fold, respectively, compared with detergent activation."( Glucuronidation of all-trans-retinoic acid and 5,6-epoxy-all-trans-retinoic acid. Activation of rat liver microsomal UDP-glucuronosyltransferase activity by alamethicin.
Lehman, PA; Little, JM; Nowell, S; Radominska, A; Samokyszyn, V, 1997
)
"Alamethicin is an alpha-helical peptide that forms voltage-activated ion channels. "( Simulation studies of alamethicin-bilayer interactions.
Biggin, PC; Breed, J; Sansom, MS; Son, HS, 1997
)
"Alamethicin is a 20 amino acid, potentially helical peptaibol which forms voltage-dependent ion channels in bilayer systems. "( Functional modifications of alamethicin ion channels by substitution of glutamine 7, glycine 11 and proline 14.
Bienert, M; Dathe, M; Kaduk, C, 1998
)
"Alamethicin is an alpha-helical channel-forming peptide, which inserts into lipid bilayers in a voltage-dependent, asymmetrical fashion. "( Alamethicin helices in a bilayer and in solution: molecular dynamics simulations.
Berendsen, HJ; Sansom, MS; Tieleman, DP, 1999
)
"Alamethicin is a helical 20-amino acid voltage-gated channel-forming peptide, which is known to exhibit segmental flexibility in solution along its backbone near alpha-methylalanine (MeA)-10 and Gly-11. "( The role of proline and glycine in determining the backbone flexibility of a channel-forming peptide.
Cafiso, DS; Duclohier, H; Jacob, J, 1999
)
"Alamethicin is a 20 amino acid antibiotic peptide produced by the soil fungus Trichoderma viride. "( Backbone dynamics of detergent-solubilized alamethicin from amide hydrogen exchange measurements.
O'Neil, JD; Szymczyna, B; Yee, A, 1999
)
"Alamethicin is an amphipathic alpha-helical peptide that forms ion channels. "( Surface binding of alamethicin stabilizes its helical structure: molecular dynamics simulations.
Berendsen, HJ; Sansom, MS; Tieleman, DP, 1999
)
"Alamethicin is a 20-residue channel-forming peptide that forms a stable amphipathic alpha-helix in membrane and membrane-mimetic environments. "( The mechanism of channel formation by alamethicin as viewed by molecular dynamics simulations.
Berendsen, HJ; Sansom, MS; Tieleman, DP, 1999
)
"Alamethicin is a 20-amino acid antibiotic peptide that forms voltage-gated ion channels in lipid bilayers. "( Continuum solvent model calculations of alamethicin-membrane interactions: thermodynamic aspects.
Ben-Tal, N; Cafiso, DS; Kessel, A, 2000
)
"Alamethicin (Alm) is a 20 residue peptide which forms a kinked alpha-helix in membrane and membrane-mimetic environments. "( Alamethicin channels in a membrane: molecular dynamics simulations.
Berendsen, HJ; Breed, J; Sansom, MS; Tieleman, DP, 1998
)
"Alamethicin is a hydrophobic antibiotic peptide 20 amino acids in length. "( Calculations suggest a pathway for the transverse diffusion of a hydrophobic peptide across a lipid bilayer.
Ben-Tal, N; Kessel, A; Schulten, K, 2000
)
"Alamethicin is a peptide antibiotic, which usually forms ion channels in various association states."( Alamethicin-leucine zipper hybrid peptide: a prototype for the design of artificial receptors and ion channels.
Fukuda, M; Futaki, S; Niwa, M; Omote, M; Sugiura, Y; Yagami, T; Yamauchi, K, 2001
)
"Alamethicin is a channel-forming peptide antibiotic that produces a highly voltage-dependent conductance in planar bilayers. "( Determination of the molecular dynamics of alamethicin using 13C NMR: implications for the mechanism of gating of a voltage-dependent channel.
Cafiso, DS; Ellena, JF; Kelsh, LP, 1992
)
"Alamethicin is an antibiotic which produces voltage gated channels in lipid bilayer membranes. "( A three state model for alamethicin conductance in bilayer membranes.
Bruner, LJ, 1985
)

Effects

ExcerptReference
"Alamethicin channels have been modelled as approximately parallel bundles of transbilayer helices containing between N = 4 and 8 helices per bundle. "( Alamethicin channels - modelling via restrained molecular dynamics simulations.
Biggin, PC; Breed, J; Kerr, ID; Sansom, MS; Smart, OS, 1997
)

Actions

ExcerptReference
"Alamethicin appears to allow voltage-dependent lipid exchange ("flip-flop") between leaflets of a planar bilayer. "( Voltage-dependent lipid flip-flop induced by alamethicin.
Hall, JE, 1981
)

Treatment

Alamethicin-treated mitochondria show high rotenone-sensitive NADH oxidase, NADH-quinone reductase, and oligomycin-sensitive ATPase activities.

ExcerptReference
"Alamethicin-treated mitochondria show high rotenone-sensitive NADH oxidase, NADH-quinone reductase, and oligomycin-sensitive and carboxyatractylate-insensitive ATPase activities."( In situ assay of the intramitochondrial enzymes: use of alamethicin for permeabilization of mitochondria.
Bakeeva, LE; Gostimskaya, IS; Grivennikova, VG; Vinogradov, AD; Zharova, TV, 2003
)
"Alamethicin-treated mitochondria catalyzed the rotenone-sensitive NADH-quinone reductase reaction with exogenousely added NADH and quinone-acceptor at the rates expected if the enzyme active sites would be freely accessible for the substrates."( Catalytic activity of NADH-ubiquinone oxidoreductase (complex I) in intact mitochondria. evidence for the slow active/inactive transition.
Grivennikova, VG; Kapustin, AN; Vinogradov, AD, 2001
)

Toxicity

ExcerptReference
" gigas embryos appeared very sensitive to all the metabolites examined with higher toxic effects for long-sequence peptides (EC50 ranging from 10 to 64 nM)."( Toxicity assessment of peptaibols and contaminated sediments on Crassostrea gigas embryos.
Amiard, JC; Montagu, M; Poirier, L; Pouchus, YF; Quiniou, F; Ruiz, N, 2007
)

Dosage Studied

ExcerptReference
" These results were then correlated with the effects of alamethicin on biological membranes in vitro as observed by optical microscopy and microculture tetrazolium assay on the tumour cells HeLa to provide a comprehensive and quantitative analysis of these effects, based on a dose-response relationship."( Vertical ordering sensitivity of solid supported DPPC membrane to alamethicin and the related loss of cell viability.
Bordi, F; Castellano, C; Congiu, A; Dell'Unto, F; Domenici, F; Olmati, C; Tiezzi, A; Triggiani, D, 2015
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
volatile benzenoid biosynthesis I (ester formation)119

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki0.61900.00000.54057.7600AID281162
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (21)

Processvia Protein(s)Taxonomy
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID559754Antibacterial activity against Aeromonas bestiarum DSM 13956 in presence of silver nanoparticles2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559736Antibacterial activity against Aeromonas bestiarum DSM 139562009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559741Antibacterial activity against Micrococcus luteus DSM 17902009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559744Antibacterial activity against Enterobacter helveticus DSM 18396 in presence of silver nitrate2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559735Antibacterial activity against Enterobacter helveticus DSM 183962009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559743Antibacterial activity against Acinetobacter calcoaceticus DSM 586 in presence of silver nitrate2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559745Antibacterial activity against Aeromonas bestiarum DSM 13956 in presence of silver nitrate2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID279005Antibacterial activity against 10^6 CFU/ml Mycoplasma pulmonis MpUR1.1 assessed as viable cell count after 2 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Activities of antimicrobial peptides and synergy with enrofloxacin against Mycoplasma pulmonis.
AID279004Antibacterial activity against 10^6 CFU/ml Mycoplasma pulmonis MpUR1.1 after 48 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Activities of antimicrobial peptides and synergy with enrofloxacin against Mycoplasma pulmonis.
AID559738Antibacterial activity against Pseudomonas fluorescens DSM 500902009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559750Antibacterial activity against Micrococcus luteus DSM 1790 in presence of silver nitrate2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID279016Antibacterial activity against 10^6 CFU/ml log-phase Mycoplasma pulmonis MpUR1.1 assessed as viable cell count at 6.25 uM after 24 hrs relative to control2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Activities of antimicrobial peptides and synergy with enrofloxacin against Mycoplasma pulmonis.
AID559756Antibacterial activity against Pseudomonas fluorescens DSM 50090 in presence of silver nanoparticles2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID279007Ratio of MBC to MIC for Mycoplasma pulmonis MpUR1.12007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Activities of antimicrobial peptides and synergy with enrofloxacin against Mycoplasma pulmonis.
AID281161Displacement of [3H]N-methyl-scopolamine from human muscarinic M2 receptor expressed in CHOK1 cells at 10 uM relative to control2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 2).
AID559748Antibacterial activity against Bacillus subtilis DSM 347 in presence of silver nitrate2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559747Antibacterial activity against Pseudomonas fluorescens DSM 50090 in presence of silver nitrate2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID279011Antibacterial activity against 10^6 CFU/ml log-phase Mycoplasma pulmonis MpUR1.1 assessed as viable cell count at 6.25 uM after 1 hr relative to control2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Activities of antimicrobial peptides and synergy with enrofloxacin against Mycoplasma pulmonis.
AID559751Antibacterial activity against Escherichia coli DSM 498 in presence of silver nanoparticles2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559746Antibacterial activity against Proteus myxofaciens DSM 4482 in presence of silver nitrate2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID561113Antibacterial activity against Escherichia coli DSM 4982009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559749Antibacterial activity against Kocuria rhizophila DSM 348 in presence of silver nitrate2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559752Antibacterial activity against Acinetobacter calcoaceticus DSM 586 in presence of silver nanoparticles2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559753Antibacterial activity against Enterobacter helveticus DSM 18396 in presence of silver nanoparticles2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559759Antibacterial activity against Micrococcus luteus DSM 1790 in presence of silver nanoparticles2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559758Antibacterial activity against Kocuria rhizophila DSM 348 in presence of silver nanoparticles2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559740Antibacterial activity against Kocuria rhizophila DSM 3482009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559737Antibacterial activity against Proteus myxofaciens DSM 44822009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559757Antibacterial activity against Bacillus subtilis DSM 347 in presence of silver nanoparticles2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559755Antibacterial activity against Proteus myxofaciens DSM 4482 in presence of silver nanoparticles2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID281162Displacement of [3H]N-methyl-scopolamine from human muscarinic M3 receptor expressed in CHOK1 cells2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 2).
AID559742Antibacterial activity against Escherichia coli DSM 498 in presence of silver nitrate2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559739Antibacterial activity against Bacillus subtilis DSM 3472009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID279012Antibacterial activity against 10^6 CFU/ml growth-phase Mycoplasma pulmonis MpUR1.1 assessed as viable cell count after 2 hrs relative to control2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Activities of antimicrobial peptides and synergy with enrofloxacin against Mycoplasma pulmonis.
AID559734Antibacterial activity against Acinetobacter calcoaceticus DSM 5862009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559760Toxicity in human erythrocytes assessed as hemolysis by serial dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (607)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990155 (25.54)18.7374
1990's156 (25.70)18.2507
2000's167 (27.51)29.6817
2010's113 (18.62)24.3611
2020's16 (2.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews35 (5.65%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other584 (94.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]